Qingdian Mu

ORCID: 0000-0002-8504-2861
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Trace Elements in Health
  • Heavy Metal Exposure and Toxicity
  • RNA regulation and disease
  • Cancer Cells and Metastasis
  • Child Nutrition and Water Access
  • Iron Metabolism and Disorders
  • Gastrointestinal Tumor Research and Treatment
  • Mercury impact and mitigation studies
  • Hemoglobinopathies and Related Disorders
  • Polysaccharides and Plant Cell Walls
  • Seaweed-derived Bioactive Compounds
  • Genomics, phytochemicals, and oxidative stress
  • Pancreatic and Hepatic Oncology Research
  • Cancer therapeutics and mechanisms
  • Fibroblast Growth Factor Research
  • PI3K/AKT/mTOR signaling in cancer

Second Affiliated Hospital of Zhejiang University
2025

Zhejiang University
2019-2021

University of South China
2021

Mudanjiang Medical University
2016

Cisplatin is regularly used in the treatment of lung cancer.However, its efficacy limited because drug resistance.In this study, we found that Akt expression and activity was increased cancer cells with acquired cisplatin resistance (A549/DDP H460/DDP cells) when compared to their parental cells.Inhibition phosphatidylinositol 3-kinase (PI3K)/Akt kinase by natural inhibitor, Wortmannin, could sensitize DDP-resistant DDP reverse resistance.Combination Wortmannin capable increasing mortality...

10.4149/304_150806n433 article EN Neoplasma 2016-01-01
Coming Soon ...